Action KNE KANE BIOTECH INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Kane Biotech Inc.

Actions

KNE

CA4838092084

Marché Fermé - Toronto S.E.
Autres places de cotation
 20:32:49 07/06/2024 		Varia. 5j. Varia. 1 janv.
0,13 CAD 0,00 % Graphique intraday de Kane Biotech Inc. +4,00 % +62,50 %
23/05 La perte de Kane Biotech au premier trimestre s'aggrave malgré la hausse des revenus ; la société devrait enregistrer un gain au deuxième trimestre à la suite de la vente de STEM Animal Health MT
23/05 Kane Biotech Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Kane Biotech Announces First Quarter 2024 Financial Results
GL
Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024
AQ
Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map
GL
Kane Biotech Expands its Wound Care Portfolio with Patented Schultz Biofilm Wound Map
AQ
Kane Biotech to Host Investor Webinar
GL
Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products
GL
Canadian Investment Regulatory Organization Trade Resumption - KNE
AQ
Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health
GL
Canadian Investment Regulatory Organization Trading Halt - KNE
AQ
Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results
GL
Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health
GL
Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow
GL
Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow
AQ
Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award
GL
Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair
GL
Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair
AQ
Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray
GL
Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray
AQ
Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium
GL
Kane Biotech Announces Special Meeting of Shareholders
GL
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action KNE
  4. Actualités Kane Biotech Inc.
  5. Communiqués